Page 7 - Mycell Technology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Relay Medical Corp.: Relay Medical Reports Glow LifeTech Secures Exclusive North American Rights to ArtemiC Following Successful COVID-19 Phase II Clinical Trial Relay" or the " Company"), a technology developer and innovator, and Glow LifeTech Ltd. (" Glow"), a private company in which Relay holds a significant equity interest, are pleased to report that Glow has executed an agreement with Swiss Pharmacan AG ("the agreement") for exclusive North American and Carribean sales and distribution rights for ArtemiC , a natural health product based on Glow's MyCell Technology ("MyCell") which recen...

(2) Glow LifeTech has the exclusive rights for MyCell Technology in the United States, Canada and Mexico for one of the primary ingredients used in ArtemiC, a COVID-19 Treatment Candidate with successful Phase II Clinical Results The formulation statistically significantly improved the clinical recovery of COVID-19 patients in the treatment group in comparison with placebo and 100% of the patients in the treatment group fully recovered within 15 days Positive results from a phase II double blind randomized controlled clinical trial show the MyCell Technology ArtemiC formulation, successfully ...